NEW YORK (
) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.
Sanofi-Aventis, a healthcare company, engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company has a P/E ratio of 18.4, above the average drugs industry P/E ratio of 12.2 and below the S&P 500 P/E ratio of 22.6. Sanofi-Aventis has a market cap of $89.5 billion and is part of the
industry. Shares are up 6% year to date as of the close of trading on Friday.
You can view the full
or get investment ideas from our